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Identity 
Other names: DHRD, DRAD, FBLN3, FBNL, 
FIBL-3, MLVT, MTLV, S1-5 




The EFEMP1 coding region extends over a genomic 
interval of 56485 bp and comprises 10 exons.  
EFEMP1 proximal promoter lacks TATA or CAAT 
regulatory boxes and is rich with CG residues. 
EFEMP1 expression is repressed by promoter 
methylation in several cancer types and cancer cell 
lines. Primers used to detect EFEMP1 promoter 
methylation are show in figures 2 and 3. 
Protein 
Note 
The two transcription variants encode the same 
EFEMP1 protein of 493-amino acids with a 
molecular mass of ~ 55 kDa. Consecutive exons from 
4 to 9 encode tandem arrays of epidermal growth-
factor (EGF)-like domains.  
There is no EFEMP1 ortholog in non-mammalian 
species, indicating its recent evolution in higher 
vertebrates with intragenic exon duplications.  
There are 92-94% similarity at protein level among 
EFEMP1 of human, rat and mouse. 
Description 
EFEMP1 belongs to seven-member family of 
secreted glycoproteins characterized by a N-terminal 
signal peptide, a tandem repeat of EGF-like domains 
and a unique C-terminal fibulin-type module. 
Expression 
EFEMP1 is broadly expressed throughout the body 
during development and in adult tissues. It is highly 




EFEMP1 is one member of fibulins that serve to 
modulate cellular behavior and functions by 
connecting and integrating multiple partner moleculs 
in extracellular compartment. EFEMP1 is likely to 
contribute the integrity of basement membrane zones 
and anchor other extracellular matrix structures such 
as elastic fibers to basement membranes. Studies 
based on Efemp1 knock-out mouse implicate 
EFEMP1 function in withholding tissue integrity by 
stimulating the expression of Timp1 and Timp3 and 
inhibiting the expression and activities of matrix 
metalloproteinase Mmp2, and Mmp9 (Rahn et al., 
2009). EFEMP1 interacts with TIMP3 (Klenotic et 
al., 2004) and hepatitis B virus X antigen (Sun et al., 
1998). EFEMP1 suppresses endothelial cell spouting 
and antagonizes angiogenesis in vivo (Albig et al., 
2006). EFEMP1 interacts with EGFR (Camaj et al., 
2009).  
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Figure 1. Three transcripts were reported in Genebank for variant 1 (NM_004105), variant 2 (NM_001039348), and variant 3 
(NM_001039349). NM_004105 has been permanently suppressed because currently there is insufficient support for the transcript. 







Figure 2. Primers used to detect methylation of EFEMP1 promoter in cancer. 
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Figure 3. EFEMP1 proximal promoter and sequence upstream of translation start site. Three SP1-binding sites and an estrogen 
response element (ERE) binding site are underscored, CG residues are marked in green, exons in uppercase, and MSP/BGS primer 
locations in boldface with sequences shown in B. 
 
However, opposing effects from EFEMP1 on EGFR-
AKT signaling activity were reported in different 
cancer cells, to promote (Camaj et al., 2009) or 
suppress (Hu et al., 2011; Hwang et al., 2010; Kim et 
al., 2012) cancer cell migration/invasion and/or in 
vivo tumor growth.  
A Delta-Serrate-Lag motif in EGF-like module with 
insertion has been revealed to be responsible for 
EFEMP1-mediated activation of Notch signaling in 
glioma cells (Hu et al., 2012). 
Homology 
EFEMP1 shares homology with the other members of 




A single mutation of EFEMP1 gene at R345W was  
identified in patients with Malattia Leventinese (ML) 
and Doyne honeycombe retinal dystrophy (DHRD) 
(Stone et al., 1999).  
Severe atropy of the retina was observed in patients 
with this mutation, including absence of 
photoreceptor and RPE cells, and large fibrous scars 
in the macular region.  
This mutation was reported to cause protein 
misfolding, so that it is secreted inefficiently and 
retained within cells (Marmorstein et al., 2002).  
Comparison of pathological features of Efemp1 
knockout and R345W knock-in mice suggests 
R345W mutation in causing macular degeneration is 
not due to loss of EFEMP1, so it is likely that the 
mutation has an added detrimental effect that alters 
Bruch's membrane to a greater extent than other 
structures (Fu et al., 2007; McLaughlin et al., 2007). 
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Figure 4. Domain structures of EFEMP1 and modular gene structure for EGF-like domains based on variant 2. DSL, Delta-Serrate-






EFEMP1 was found to be highly expressed in 
malignant gliomas and in glioma cells with activation 
of Notch signaling (Hu et al., 2012; Hu et al., 2009).  
However, EFEMP1 expression is positively 
associated with survival of patients with the highest 
grade of glioma - glioblastoma multiforme (GBM) 
and consistently, EFEMP1 was shown to suppress 
highly proliferative GBM cell growth in vivo by 
attenuation of EGFR-AKT signaling activities and 
VEGFA-induced angiogenesis (Hu et al., 2011). 
Along with activation of Notch pathway, EFEMP1 
was shown to enhance migration/invasion and growth 
in vivo by glioma cells high in Notch signaling and 
stem-like feature (Hu et al., 2012). The contradictory 
roles of EFEMP1 to the growth of different glioma 
cells suggest EFEMP1 context-dependent function, 
thus could be an interesting gene to study glioma 
initiation, progression and tumor heterogeneity. 
Breast cancer 
Note 
Hypermethylation of EFEMP1 promoter was found to 
be the major cause of EFEMP1 expression down-
regulation in 50-60% sporadic breast cancer (SBC). 
Tumor suppressive function of EFEMP1 is implicated 
in SBC by a favorable prognosis effect of EFEMP1 
expression to survival, particularly node-positive 
patients who received adjuvant anthracycline-based 
chemotherapy, but not in those treated by either 
cyclophosphamide-methotrexate-5-fluorouracil 
(CMF) or tamoxifen (Sadr-Nabavi et al., 2009). 
Cervical cancer 
Note 
EFEMP1 protein expression was found to be 
significantly higher in cervical carcinoma with lymph 
node metastasis and correlates with poor patient 
survival (En-lin et al., 2010). Tumor-promoting effect 
of EFEMP1 in cervical cancer is supported by its 
function in promoting growth in vivo and in vitro 




Hypermethylation of EFEMP1 promoter was reported 
in 38,8% colorectal cancer (CRC), which is 
correlated with downregulation of EFEMP1 
expression and cancer progression to advanced 
pathological stage with lymph node metastasis. 
Tumor suppressive function of EFEMP1 is implicated 
in CRC by a favorable prognosis effect of EFEMP1 
expression to overall survival and disease-free 
survival (Tong et al., 2011). 
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Liver cancer 
Note 
Hypermethylation of EFEMP1 promoter was reported 
in 50% hepatocellular carcinoma (HCC), which is 
correlated with downregulation of EFEMP1 
expression. Tumor suppressive function of EFEMP1 
is implicated in liver cancer by unfavorable prognosis 




Hypermethylation of EFEMP1 promoter was 
independently reported by two laboratories in 36% 
and 43% of non-small cell lung carcinoma (NSCLC), 
while it was rarely found in the matched normal 
samples (Wang et al., 2010; Yue et al., 2007; Zhang 
et al., 2011).  
It is correlated with downregulation of EFEMP1 
expression and cancer progression to advanced 
pathological stage and lymph node metastasis.  
Tumor suppressive function of EFEMP1 in lung 
cancer cell is demonstrated by its suppression effect 
on anchorage independent growth and in vitro 
invasion via suppression the expression of matrix 
metalloproteinase, including MMP2, MMP7, and 
MMP9 (Kim et al., 2012). 
Nasopharyngeal carcinoma 
Note 
Hypermethylation of EFEMP1 promoter has been 
revealed in nasopharyngeal carcinoma (NPC) 
tumours compared with normal tissues. 
Downregulation of EFEMP1 expression was found in 
NPC at advanced lymph node-metastasis stages and a 
poor 5-year survival rate.  
Tumor suppressive function of EFEMP1 in NPC is 
revealed by suppressing migration and invasion of 
NPC-derived cells and correspondingly decreasing 
the AKT phosphorylation (Hwang et al., 2010). 
Pancreatic cancer 
Note 
EFEMP1 was reported to bind EGFR and activate 
MAPK and AKT pathways in pancreatic carcinoma 
cells and promote in vivo tumor growth with a 
stimulation of VEGFA production by tumors (Camaj 
et al., 2009; Seeliger et al., 2009). 
Prostate cancer 
Note 
Hypermethylation of EFEMP1 promoter was reported 
in 95,3% of prostate cancer (PCa) but 13,4% of 
benign prostate hyperplasia (BPH), and EFEMP1 
expression was significantly higher in tissue samples 
from patients with BPH than in those with PCa (Kim 
et al., 2011). 
Werner syndrome 
Note 
S1-5 mRNA is overexpressed in Werner syndrome 
and senescent human diploid fibroblasts (Lecka-
Czernik et al., 1995). 
Adult height 
Note 
The EFEMP1 locus is one of 20 loci identified in a 
genome-wide association analysis that influence adult 
height (Okada et al., 2010). 
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